Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Phase 1b results in Parkinsonís
May 2019
SHARING OPTIONS:

SAN DIEGO & CAMBRIDGE, Mass.—Neurocrine Biosciences Inc. and Voyager Therapeutics Inc. have announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease. The primary objectives of the trial were to assess the safety, tolerability and distribution of ascending doses of VY-AADC administered under MRI guidance to the putamen, a brain region associated with impaired motor function in Parkinson’s disease.
 
“The interim results from this Phase 1b trial demonstrated that administration of VY-AADC to the putamen using a novel technique, which included intraoperative monitoring with magnetic resonance imaging guidance, facilitated targeted delivery of the investigational gene therapy,” said Dr. Chad Christine, a professor of neurology at the University of California, San Francisco, and investigator in the Phase 1b trial. “Additionally, administration of VY-AADC resulted in dose-dependent increases in AADC enzyme expression and improvements in clinical measures and has been well tolerated to date.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.